The Metastatic Challenge: Matching Preclinical Models to Late-Stage Disease In the first two posts of this 2026 series (syngeneic tumor models blog and beyond subcutaneous models blog), we examined how tumor immunophenotype shapes response to immune checkpoint inhibitors (ICI), and
Beyond Subcutaneous Models: Rethinking Implantation Site in Preclinical Oncology In our first post of this series, we examined how tumor immunophenotype and combination treatment strategy influence checkpoint inhibitor efficacy in syngeneic models. We closed with a question: what happens when
Syngeneic Tumor Models: The Gold Standard for Preclinical Immunotherapy Testing Cancer immunotherapy has transformed oncology, yet translating early efficacy into consistent clinical success remains challenging. Central to this effort is the need for preclinical models that genuinely reflect how tumors
Antibody Drug Conjugates (ADCs) combine targeting precision of monoclonal antibodies with cytotoxic agents. They selectively deliver a highly toxic payload to tumors, which prevents systemic toxicity, offering higher therapeutic index and reduced risk of side effects. Recent decades brought breakthroughs
Cytokines and their receptors orchestrate intricate immune responses, yet when dysregulated, they fuel persistent inflammation and tissue damage, causing diseases like psoriasis and rheumatoid arthritis. Despite their potential, the pleiotropic nature of cytokines has historically led to dose-limiting toxicity or
The Importance of Preclinical Models in Epilepsy Drug Discovery Epilepsy is a chronic neurological condition affecting more than 50 million people worldwide and one of the most intensely investigated therapeutic areas in neuroscience. Despite many antiepileptic drugs existing on the
Antibody-drug conjugates (ADCs) are complex therapeutics that link antibodies to cytotoxic payloads, offering a targeted approach to mitigate the systemic toxicity of conventional chemotherapy. Despite rapid progress in ADC engineering, significant challenges remain, related both to technical limitations and to
Multispecific ADCs: Solutions to Oncology’s Toughest Hurdles Antibody drug conjugates (ADCs) combine carefully engineered monoclonal antibodies with chemotherapy drugs, allowing for targeted therapeutic delivery to cancer cells. Targeting tumors with ADCs can mitigate systemic toxic effects, which are common with
Psoriasis: Patient Impact and the Path to Innovation Psoriasis is more than a skin condition, it is often a lifelong, systemic autoimmune disease that may increase the risk of other serious health complications such as heart disease and diabetes, and
Unlocking the Potential of Targeted Protein Degradation In the realm of novel therapeutics, targeted protein degradation has serendipitously emerged as a game-changer, transforming “undruggable” proteins into viable candidates for therapeutic intervention. By hijacking the cell’s innate ubiquitin-proteasome system (UPS), technologies
START YOUR JOURNEY